Top Stock Reports for Berkshire Hathaway, Roche & RTX
Ahead of the market, research reports interpret the morning’s economic releases and their likely impact on trading. Research covered Berkshire Hathaway, Roche and RTX. Strong growth from key products offset declining legacy-drug revenues, with a steady commercial aerospace recovery and robust defense orders. RTX has a Neutral rating; a $126.2 million backlog, up 45% year over year, supports visibility. Roche rose 45.2% and RTX 33%.